<code id='BAFF445015'></code><style id='BAFF445015'></style>
    • <acronym id='BAFF445015'></acronym>
      <center id='BAFF445015'><center id='BAFF445015'><tfoot id='BAFF445015'></tfoot></center><abbr id='BAFF445015'><dir id='BAFF445015'><tfoot id='BAFF445015'></tfoot><noframes id='BAFF445015'>

    • <optgroup id='BAFF445015'><strike id='BAFF445015'><sup id='BAFF445015'></sup></strike><code id='BAFF445015'></code></optgroup>
        1. <b id='BAFF445015'><label id='BAFF445015'><select id='BAFF445015'><dt id='BAFF445015'><span id='BAFF445015'></span></dt></select></label></b><u id='BAFF445015'></u>
          <i id='BAFF445015'><strike id='BAFF445015'><tt id='BAFF445015'><pre id='BAFF445015'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:comprehensive    Page View:6
          King Street Properties’ Pathway Devens campus. -- biotech coverage from STAT
          Pat Greenhouse/Globe Staff

          MORRISVILLE, N.C. — Ten minutes from the Raleigh airport, the future of biotech is under construction.

          On either side of a new stretch of four-lane highway sit two $1 billion biomanufacturing campuses, which will bring a combined 2.5 million square feet of research and development and advanced manufacturing space to a region that has become the No. 1 place where North America makes prescription drugs.

          advertisement

          One campus, called Pathway Triangle, is being built by a developer from Boston, King Street Properties. King Street — which has projects in Cambridge, Waltham, Allston, and Lexington — is building a similarly vast biomanufacturing campus in Devens. But these days it also sees a land of opportunity 700 miles to the south, in North Carolina.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          Insmed lung disease drug hits target in key Phase 3 trial
          Insmed lung disease drug hits target in key Phase 3 trial

          AdobeAnexperimentaldrugfromInsmedIncorporatedsuccessfullyreducedlungproblemsamongpatientswithanairwa

          read more
          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more

          Readout LOUD podcast: Live from the 2023 STAT Summit

          STATWhatifCRISPRisn’tallthatcommercial?HowdoestheNurOwnstoryend?Andhowdoyoupronounce“Bayer”?Wecovera